Cargando…

Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments

Evidence is accumulating showing that septic acute kidney injury (AKI) is different from non-septic AKI. Specifically, a large body of research points to apoptotic processes underlying septic AKI. Unravelling the complex and intertwined apoptotic and immuno-inflammatory pathways at the cellular leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Honore, Patrick M, Jacobs, Rita, Joannes-Boyau, Olivier, De Regt, Jouke, Boer, Willem, De Waele, Elisabeth, Collin, Vincent, Spapen, Herbert D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224527/
https://www.ncbi.nlm.nih.gov/pubmed/21906387
http://dx.doi.org/10.1186/2110-5820-1-32
_version_ 1782217402490028032
author Honore, Patrick M
Jacobs, Rita
Joannes-Boyau, Olivier
De Regt, Jouke
Boer, Willem
De Waele, Elisabeth
Collin, Vincent
Spapen, Herbert D
author_facet Honore, Patrick M
Jacobs, Rita
Joannes-Boyau, Olivier
De Regt, Jouke
Boer, Willem
De Waele, Elisabeth
Collin, Vincent
Spapen, Herbert D
author_sort Honore, Patrick M
collection PubMed
description Evidence is accumulating showing that septic acute kidney injury (AKI) is different from non-septic AKI. Specifically, a large body of research points to apoptotic processes underlying septic AKI. Unravelling the complex and intertwined apoptotic and immuno-inflammatory pathways at the cellular level will undoubtedly create new and exciting perspectives for the future development (e.g., caspase inhibition) or refinement (specific vasopressor use) of therapeutic strategies. Shock complicating sepsis may cause more AKI but also will render treatment of this condition in an hemodynamically unstable patient more difficult. Expert opinion, along with the aggregated results of two recent large randomized trials, favors continuous renal replacement therapy (CRRT) as preferential treatment for septic AKI (hemodynamically unstable). It is suggested that this approach might decrease the need for subsequent chronic dialysis. Large-scale introduction of citrate as an anticoagulant most likely will change CRRT management in intensive care units (ICU), because it not only significantly increases filter lifespan but also better preserves filter porosity. A possible role of citrate in reducing mortality and morbidity, mainly in surgical ICU patients, remains to be proven. Also, citrate administration in the predilution mode appears to be safe and exempt of relevant side effects, yet still requires rigorous monitoring. Current consensus exists about using a CRRT dose of 25 ml/kg/h in non-septic AKI. However, because patients should not be undertreated, this implies that doses as high as 30 to 35 ml/kg/h must be prescribed to account for eventual treatment interruptions. Awaiting results from large, ongoing trials, 35 ml/kg/h should remain the standard dose in septic AKI, particularly when shock is present. To date, exact timing of CRRT is not well defined. A widely accepted composite definition of timing is needed before an appropriate study challenging this major issue can be launched.
format Online
Article
Text
id pubmed-3224527
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-32245272011-12-16 Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments Honore, Patrick M Jacobs, Rita Joannes-Boyau, Olivier De Regt, Jouke Boer, Willem De Waele, Elisabeth Collin, Vincent Spapen, Herbert D Ann Intensive Care Review Evidence is accumulating showing that septic acute kidney injury (AKI) is different from non-septic AKI. Specifically, a large body of research points to apoptotic processes underlying septic AKI. Unravelling the complex and intertwined apoptotic and immuno-inflammatory pathways at the cellular level will undoubtedly create new and exciting perspectives for the future development (e.g., caspase inhibition) or refinement (specific vasopressor use) of therapeutic strategies. Shock complicating sepsis may cause more AKI but also will render treatment of this condition in an hemodynamically unstable patient more difficult. Expert opinion, along with the aggregated results of two recent large randomized trials, favors continuous renal replacement therapy (CRRT) as preferential treatment for septic AKI (hemodynamically unstable). It is suggested that this approach might decrease the need for subsequent chronic dialysis. Large-scale introduction of citrate as an anticoagulant most likely will change CRRT management in intensive care units (ICU), because it not only significantly increases filter lifespan but also better preserves filter porosity. A possible role of citrate in reducing mortality and morbidity, mainly in surgical ICU patients, remains to be proven. Also, citrate administration in the predilution mode appears to be safe and exempt of relevant side effects, yet still requires rigorous monitoring. Current consensus exists about using a CRRT dose of 25 ml/kg/h in non-septic AKI. However, because patients should not be undertreated, this implies that doses as high as 30 to 35 ml/kg/h must be prescribed to account for eventual treatment interruptions. Awaiting results from large, ongoing trials, 35 ml/kg/h should remain the standard dose in septic AKI, particularly when shock is present. To date, exact timing of CRRT is not well defined. A widely accepted composite definition of timing is needed before an appropriate study challenging this major issue can be launched. Springer 2011-08-09 /pmc/articles/PMC3224527/ /pubmed/21906387 http://dx.doi.org/10.1186/2110-5820-1-32 Text en Copyright ©2011 Honore et al; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Honore, Patrick M
Jacobs, Rita
Joannes-Boyau, Olivier
De Regt, Jouke
Boer, Willem
De Waele, Elisabeth
Collin, Vincent
Spapen, Herbert D
Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments
title Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments
title_full Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments
title_fullStr Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments
title_full_unstemmed Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments
title_short Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments
title_sort septic aki in icu patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224527/
https://www.ncbi.nlm.nih.gov/pubmed/21906387
http://dx.doi.org/10.1186/2110-5820-1-32
work_keys_str_mv AT honorepatrickm septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments
AT jacobsrita septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments
AT joannesboyauolivier septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments
AT deregtjouke septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments
AT boerwillem septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments
AT dewaeleelisabeth septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments
AT collinvincent septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments
AT spapenherbertd septicakiinicupatientsdiagnosispathophysiologyandtreatmenttypedosingandtimingacomprehensivereviewofrecentandfuturedevelopments